Naturegenic Inc. operates as a wholly-owned subsidiary of the Korean biotechnology firm G+FLAS Life Sciences. Under a licensing agreement, Naturegenic utilizes G+FLAS’ CRISPR-mgCas12a technology known as “CRISPR SEL ONLI” to advance cellular gene therapy solutions for genetic disorders. Through this innovative technology, Naturegenic replaces faulty genes with fully functional copies of the corresponding wild-type genes.